Article Text

AB0084 Serum Levels of Syndecan-1 and Organ Involvement in Systemic Lupus Erythematosus
  1. N. Fajardo-Robledo1,2,
  2. V. Diaz-Rizo3,4,
  3. A. Rocha-Muñoz5,
  4. J. Muñoz-Valle6,
  5. L. Gonzalez-Lopez7,
  6. J. Gamez-Nava8
  1. 1UMAE, Hospital de Especialidades Centro Medico de Occidente, Instituto Mexicano de Seguro Social
  2. 2Doctorado en Farmacología, Universidad de Guadalajara, Guadalajara
  3. 3Doctorado en Ciencias Médicas, Universidad de Colima, Colima
  4. 4UMAE, Hospital de Especialidades Centro Medico de Occidente, Instituto Mexicano del Seguro Social
  5. 5Programa de Post-doctorado Doctorado en Farmacología, Universidad de Guadalajara
  6. 6Doctorado en Ciencias Biomédicas, Universidad de Guadalajara
  7. 7Departamento de Medicina Interna-Reumatología, Hospital General Regional #110, Instituto Mexicano del Seguro Social
  8. 8Unidad de Investigaciόn en Epidemiología Clínica, Centro Medico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico


Background Syndecan-1 is expressed on plasma cells surface and serum levels as reflect an activation of these cells. To date, a significant association between serum levels of syndecan-1with disease activity has been observed in a study evaluating patients with systemic lupus erythematosus (SLE). Nevertheless, to date there is a lack of information about.

Objectives Evaluate the association of syndecan-1 serum levels with disease activity and clinical variables

Methods We included 46 patients with SLE and were compared with 46 controls. Disease characteristics and treatments were assessed in patients with SLE. Serum levels of syndecan-1 and BLyS were obtained and correlated with clinical variables of the SLE patients.

Results Patients with SLE had a mean age of 42 years. From 46 patients with SLE, 30 (70%) had disease activity with a SLEDAI >3, and 21 (47%) had renal involvement. Patients with renal involvement had a trend to higher serum levels of syndecan-1 (129.7±80.4 vs. 87.1±65.4 respectively, p=0.07) Syndecan-1 correlated significantly with proteinuria (r=0.39, p=0.01). Also patients with cutaneous involvement had higher levels of syndecan-1 compared with patients without this involvement (126.5±81.3 vs. 96.2±69.2 respectively, p=0.01). Patients with higher levels of syndecan-1 also had a trend to higher doses of prednisone (r=0.28, p=0.07), and higher doses of mofetil mycophenolate (r=0.29, p=0.06) reflecting the treatment for a more severe disease activity.

Conclusions These results suggest that syndecan-1 serum levels are related with disease activity, particularly renal involvement. The potential role of this molecule should be evaluated in a prospective cohort study in order to identify if could be useful as a marker for different therapeutic outcomes in SLE.

This project was financed by a grant of Instituto Mexicano del Seguro Social: FIS/PROT/G13/1202.


  1. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1989 Nov;1(1):27-35.

  2. Minowa, K., H. Amano, S. Nakano, S. Ando, T. Watanabe, Y. Nakiri, E. Amano, Y. Tokano, S. Morimoto, and Y. Takasaki, Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus. Autoimmunity, 2011. 44(5)

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.5962

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.